Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)‘s stock had its “buy” rating restated by investment analysts at Ladenburg Thalmann Financial Services in a note issued to investors on Thursday, September 21st. They currently have a $146.00 price objective on the biopharmaceutical company’s stock, up from their prior price objective of $90.00. Ladenburg Thalmann Financial Services’ target price points to a potential upside of 20.16% from the stock’s previous close.
ALNY has been the topic of a number of other research reports. Needham & Company LLC reaffirmed a “buy” rating and issued a $85.00 price objective (down previously from $98.00) on shares of Alnylam Pharmaceuticals in a research note on Thursday, September 7th. Chardan Capital restated a “buy” rating on shares of Alnylam Pharmaceuticals in a research report on Monday, September 11th. Nomura assumed coverage on shares of Alnylam Pharmaceuticals in a research note on Thursday, September 14th. They set a “reduce” rating and a $56.00 price target on the stock. ValuEngine raised shares of Alnylam Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research note on Friday, June 2nd. Finally, Instinet assumed coverage on shares of Alnylam Pharmaceuticals in a research report on Friday, September 15th. They set a “reduce” rating and a $56.00 target price on the stock. Three equities research analysts have rated the stock with a sell rating, seven have given a hold rating and fifteen have given a buy rating to the company. Alnylam Pharmaceuticals presently has a consensus rating of “Hold” and a consensus target price of $94.33.
Shares of Alnylam Pharmaceuticals (NASDAQ:ALNY) traded up 5.5120% on Thursday, reaching $123.9661. 693,065 shares of the company were exchanged. Alnylam Pharmaceuticals has a 12-month low of $31.38 and a 12-month high of $124.64. The stock’s 50-day moving average is $81.14 and its 200 day moving average is $69.12. The firm’s market capitalization is $11.37 billion.
Alnylam Pharmaceuticals (NASDAQ:ALNY) last announced its quarterly earnings results on Wednesday, August 9th. The biopharmaceutical company reported ($1.34) EPS for the quarter, missing the consensus estimate of ($1.22) by ($0.12). The company had revenue of $15.93 million during the quarter, compared to analysts’ expectations of $23.86 million. Alnylam Pharmaceuticals had a negative return on equity of 45.53% and a negative net margin of 670.81%. The firm’s revenue for the quarter was up 82.9% compared to the same quarter last year. During the same quarter in the previous year, the firm earned ($1.05) EPS. On average, analysts forecast that Alnylam Pharmaceuticals will post ($5.19) EPS for the current year.
In other Alnylam Pharmaceuticals news, President Barry E. Greene sold 76,815 shares of Alnylam Pharmaceuticals stock in a transaction on Wednesday, September 20th. The shares were sold at an average price of $100.00, for a total value of $7,681,500.00. Following the transaction, the president now directly owns 165,399 shares of the company’s stock, valued at $16,539,900. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Corporate insiders own 4.30% of the company’s stock.
Large investors have recently made changes to their positions in the stock. Broadfin Capital LLC purchased a new stake in Alnylam Pharmaceuticals in the second quarter valued at about $14,453,000. Verition Fund Management LLC acquired a new position in shares of Alnylam Pharmaceuticals during the second quarter valued at about $1,060,000. The Manufacturers Life Insurance Company increased its holdings in shares of Alnylam Pharmaceuticals by 7.0% during the second quarter. The Manufacturers Life Insurance Company now owns 2,541 shares of the biopharmaceutical company’s stock valued at $203,000 after acquiring an additional 167 shares in the last quarter. EcoR1 Capital LLC purchased a new position in shares of Alnylam Pharmaceuticals in the 2nd quarter valued at approximately $831,000. Finally, BlueCrest Capital Management Ltd acquired a new stake in Alnylam Pharmaceuticals in the 2nd quarter worth approximately $1,304,000. 94.25% of the stock is currently owned by institutional investors.
About Alnylam Pharmaceuticals
Alnylam Pharmaceuticals, Inc is a biopharmaceutical company. The Company is engaged in the discovery, development and commercialization of ribonucleic acid (RNA) interference (RNAi) therapeutics. The Company is focused on the use of its N-acetylgalactosamine (GalNAc)-conjugate platform for delivery of small interfering RNAs (siRNAs).
Receive News & Ratings for Alnylam Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alnylam Pharmaceuticals Inc. and related companies with our FREE daily email newsletter.